Par Drugs And Chemicals Ltd.
•Add ratio to table
ABOUT
KEY POINTS
Revenue Breakup Mar 2018 • Bhavnagar: 99.2% • Ankleshwar: 0.8%
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company has delivered good profit growth of 22.9% CAGR over last 5 years
- Company is almost debt free
- Company has a healthy return on capital (ROCE) of 22.6%
- Latest quarter profit grew 41.5% YoY, showing strong momentum
- Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.27x)
CONS
- Receivables are growing faster than sales - a possible quality concern
- Growth is decelerating - 3Y profit CAGR (13.2%) trails the 5Y trend (22.9%)
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1842.00 | 36.54 | 441957.50 | 0.87 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9326.00 | 84.64 | 247576.00 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4975.00 | 86.76 | 189233.01 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1119.50 | 24.74 | 111670.55 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1365.00 | 32.72 | 110272.68 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1970.35 | 97.37 | 106460.42 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| DRREDDY | 1161.00 | 30.07 | 96906.38 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1675.45 | 25.97 | 96401.69 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2096.00 | 17.34 | 95842.92 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2277.00 | 46.04 | 94050.37 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2416.90 | 37.94 | 68210.88 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| PAR | 140.92 | 11.96 | 173.40 | 0.00 | 4.71 | 41.53 | 31.28 | 20.08 | 19.51 | 20.40 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23 | 26 | 24 | 23 | 23 | 35 | 21 | 22 | 26 | 29 | 29 | 20 | 31 | |
| 19 | 19 | 19 | 17 | 18 | 23 | 20 | 20 | 22 | 23 | 23 | 18 | 26 | |
| Operating Profit | 4 | 7 | 5 | 6 | 4 | 11 | 1 | 2 | 4 | 6 | 6 | 1 | 5 |
| OPM % | 18.05% | 28.43% | 21.79% | 26.69% | 18.75% | 32.92% | 6.69% | 10.88% | 13.67% | 21.18% | 20.65% | 7.34% | 17.25% |
| 0 | 0 | 0 | -0 | 0 | 1 | 0 | 1 | 2 | 0 | 1 | 0 | 1 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before Tax | 3 | 7 | 5 | 5 | 3 | 11 | 1 | 2 | 4 | 6 | 6 | 1 | 6 |
| Tax % | 25.15% | 25.23% | 25.16% | 27.20% | 25.15% | 25.15% | 24.68% | 27.63% | 25.67% | 25.59% | 25.62% | -2.41% | 25.55% |
| Net Profit | 2 | 5 | 3 | 4 | 3 | 9 | 1 | 2 | 3 | 4 | 5 | 1 | 5 |
| 2.01 | 3.97 | 2.78 | 3.02 | 2.06 | 6.99 | 0.47 | 1.34 | 2.70 | 3.36 | 3.90 | 0.69 | 3.83 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 33 | 49 | 42 | 46 | 56 | 61 | 75 | 96 | 96 | 101 | 109 | |
| 26 | 40 | 34 | 38 | 46 | 45 | 59 | 78 | 73 | 81 | 90 | |
| Operating Profit | 7 | 8 | 8 | 8 | 9 | 16 | 16 | 18 | 23 | 20 | 19 |
| OPM % | 21.61% | 17.35% | 18.94% | 17.71% | 16.91% | 26.36% | 21.65% | 19.02% | 23.86% | 19.31% | 17.42% |
| 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 3 | |
| Interest | 4 | 3 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 |
| Profit before Tax | 1 | 3 | 3 | 3 | 6 | 15 | 13 | 15 | 20 | 18 | 19 |
| Tax % | 58.10% | 41.95% | 41.35% | 23.72% | 20.48% | 21.15% | 27.47% | 24.84% | 25.70% | 25.47% | 24.37% |
| Net Profit | 0 | 2 | 2 | 3 | 5 | 12 | 9 | 11 | 15 | 13 | 14 |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.87 | 7.49 | 9.21 | 11.79 | 10.86 | — |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 32.28% | 0.00% | 16.69% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- 12%
- 5 Years:
- 13%
- 3 Years:
- 10%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- 31%
- 5 Years:
- 23%
- 3 Years:
- 13%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- 6%
- 3 Years:
- -9%
- 1 Year:
- 24%
RETURN ON EQUITY
- 10 Years:
- 15%
- 5 Years:
- 18%
- 3 Years:
- 17%
- Last Year:
- 14%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 3 | 3 | 3 | 4 | 6 | 6 | 12 | 12 | 12 | 12 | |
| 9 | 11 | 13 | 25 | 34 | 46 | 48 | 59 | 73 | 87 | |
| 26 | 21 | 23 | 12 | 6 | 8 | 0 | 0 | 0 | 0 | |
| Trade Payables | 6 | 8 | 5 | 5 | 6 | 7 | 11 | 8 | 5 | 11 |
| 14 | 14 | 10 | 6 | 7 | 9 | 8 | 10 | 11 | 10 | |
| Total Liabilities | 58 | 56 | 54 | 51 | 60 | 76 | 79 | 89 | 102 | 119 |
| 43 | 42 | 39 | 36 | 34 | 30 | 34 | 38 | 41 | 39 | |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 1 | 5 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25 | |
| 6 | 4 | 4 | 4 | 3 | 3 | 5 | 5 | 4 | 6 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 17 | |
| Cash & Bank | 1 | 0 | 0 | 0 | 7 | 21 | 16 | 22 | 37 | 28 |
| 9 | 10 | 11 | 11 | 15 | 18 | 23 | 23 | 6 | 5 | |
| Total Assets | 58 | 56 | 54 | 51 | 60 | 76 | 79 | 89 | 102 | 119 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 7 | 10 | 5 | 4 | 9 | 16 | 11 | 18 | 20 | 16 | |
| Cash from Investing | -0 | -2 | -1 | -0 | -1 | 0 | -3 | -7 | -6 | -25 |
| Cash from Financing | -5 | -8 | -4 | -3 | 1 | 2 | -10 | -0 | 0 | 0 |
| 1 | -1 | 0 | -0 | 7 | 14 | -5 | 6 | 14 | -9 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-05 - Par Drugs And Chemicals Limited has informed the Exchange about Copy of Newspaper Publication
2026-09-01 - Par Drugs And Chemicals Limited has informed the Exchange regarding 'Regulation 36 (1)(b)'.
2026-08-22 - Par Drugs And Chemicals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 26, 2026
2026-08-22 - Par Drugs And Chemicals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 22, 2026.
2026-08-22 - Par Drugs And Chemicals Limited has informed the Exchange regarding Appointment of M/s Maulin Shah & Associates, Cost Accountant as Cost Auditor of the Company w.e.f. April 01, 2026.
2026-08-22 - Par Drugs And Chemicals Limited has informed the Exchange regarding Appointment of Ms SIDDHPURA & CO, Internal Auditor as Internal auditor of the company w.e.f. April 01, 2026.
2026-08-22 - Par Drugs And Chemicals Limited has informed the Exchange regarding 'Outcome of Board Meeting dated 22.08.2026'.
2026-08-21 - Par Drugs And Chemicals Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-10 - Par Drugs And Chemicals Limited has informed the Exchange about Copy of Newspaper Publication
News
Recent coverage and analyst commentary for PAR
Loading news…
AI Stock Analyst
Par Drugs And Chemicals Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account